SUBSCRIBE
SUBSCRIBE
Kate Goodwin

Kate Goodwin

Contributing Writer | News & Features

Kate Goodwin hails from a background primarily in marketing. A passion for health sciences and writing led her to the biopharma news world, and she’s never looked back. She’s been writing for BioSpace for more than two years with a focus on cutting edge research, Alzheimer’s disease and pediatrics. Her free time is filled by her husband, children, Beagles, books, crochet and creative writing. She can be reached at kate.goodwin@biospace.com.

Pictured: Merck Headquarters/iStock, JHVEPhoto
Drug Development
Merck Touts Keytruda Phase III NSCLC Survival Data Ahead of FDA Decision  
The pharma giant’s anti-PD-1 therapy met its dual primary endpoint of overall survival as a treatment regimen for non-small cell lung cancer patients, as the FDA’s Oct. 16 PDUFA date looms.  
October 10, 2023
 · 
2 min read
 · 
Kate Goodwin
Amgen sign at its headquarters in Thousand Oaks, California, USA.
Policy
Amgen Completes $27.8B Horizon Acquisition Following FTC Challenge
After finally getting the green light from the Federal Trade Commission last month, Amgen has completed the buyout and expects to provide updated fiscal year 2023 guidance during its third-quarter earnings call.
October 6, 2023
 · 
2 min read
 · 
Kate Goodwin
Pictured: DNA Particle Complex/iStock, peterschrei
Deals
Kyowa Kirin Buys Orchard for Potential $478M as FDA Decision Looms
The Japan-based pharma is acquiring Orchard Therapeutics for approximately $477.6 million, if all conditions are met. Orchard’s pediatric gene therapy has a PDUFA date set for March 2024.
October 5, 2023
 · 
2 min read
 · 
Kate Goodwin
Pictured: Facade of Sanofi's headquarters in Franc
Business
Sanofi, Teva Ink Potential $1.5B Deal Aimed at Blockbuster IBD Drug
The French pharma paid $500 million upfront, with up to $1 billion in future milestone payments, to co-develop and co-commercialize Teva’s Phase II anti-TL1A antibody for inflammatory bowel disease.
October 4, 2023
 · 
2 min read
 · 
Kate Goodwin
Pictured: A doctor checks an older patient’s lungs
Investors Fuel Fountain of Youth Research with Longevity Company Funding
The call to develop therapeutics that interfere with aging, helping people live longer, healthier lives, is increasing—and experts say the market opportunity is high.
October 3, 2023
 · 
5 min read
 · 
Kate Goodwin
Pictured: Gilead's headquarters in Silicon Valley/
Drug Development
Gilead Axes Phase III Magrolimab Trial Based on Disappointing Data
After picking up magrolimab in a $4.9 billion purchase of Forty Seven, a second Phase III study is being discontinued for the anti-CD47 antibody, this time in acute myeloid leukemia.
September 27, 2023
 · 
2 min read
 · 
Kate Goodwin
Pictured: Autoimmune written on clipboard/iStock,
Drug Development
Immunovant Stock Soars on Positive Phase I Autoimmune Antibody Data
Shares were up over 60% in premarket trading on news that the company’s anti-FcRn antibody exhibited dose-dependent reductions in IgG levels, drivers of inflammation in many autoimmune diseases.
September 26, 2023
 · 
2 min read
 · 
Kate Goodwin
Pictured: AstraZeneca signage at its office in Sweden
Drug Development
AstraZeneca, Daiichi Tout Phase III Breast Cancer Data in Challenge to Gilead
The companies’ antibody-drug conjugate improved progression-free survival with a “trend in improvement” for overall survival in patients with HR-positive, HER2-low or negative breast cancer.
September 22, 2023
 · 
2 min read
 · 
Kate Goodwin
Pictured: Genentech Headquarters/iStock, Sundry Ph
Business
Genentech Doubles Down with Orionis Deal Worth up to $2B for Glue Degraders
After announcing a $1 billion radiopharma deal with PeptiDream, Genentech signed a separate deal with Orionis Biosciences for its molecular glue degraders to target cancer and neurodegeneration.
September 21, 2023
 · 
1 min read
 · 
Kate Goodwin
Pictured: Businessmen shaking hands after closing
Business
Genentech, PeptiDream Ink Potential $1B Radiopharma Deal
The Japanese biopharma will receive $40 million upfront from Genetech for R&D of its macrocyclic peptide-radioisotope drug conjugates, with another $1 billion on the line in milestone payments.
September 20, 2023
 · 
1 min read
 · 
Kate Goodwin
Astellas' headquarters for the Americas
Drug Development
Astellas Touts Izervay Phase III Geographic Atrophy Data, Eyes Label Expansion
The latest data show Izervay is safe and effective in a two-year trial. Just six weeks after securing FDA approval, Astellas plans to submit it to the regulator to expand its label for a longer treatment timeframe.
September 19, 2023
 · 
2 min read
 · 
Kate Goodwin
Pictured: Nasdaq signage and building in New York City
Deals
RayzeBio’s $311M, Neumora’s $250M IPOs Among Biotech’s Largest This Year
The two biotech companies announced initial public offering pricing Thursday, respectively, with shares beginning trading Friday and valued at more than $560 million cumulatively.
September 15, 2023
 · 
2 min read
 · 
Kate Goodwin
Pictured: Human lung anatomy concept/iStock, magic
Business
New Biotech Targets Rare Respiratory Disorders with Inhaled Gene Therapies
AlveoGene has licensed the U.K. Respiratory Gene Therapy Consortium’s InGenuiTy platform for all uses excluding the CTFR gene, which is already licensed to Boehringer Ingelheim for cystic fibrosis.
September 14, 2023
 · 
2 min read
 · 
Kate Goodwin
Pictured: Facade of Moderna's building in Massachusetts
Drug Development
Moderna Scales Back COVID Vaccine Production, Pursues mRNA Medicines Plan
The company plans to launch up to 15 new products and bring up to 50 new candidates to the clinic over the next five years as part of its growth plan, while scaling down COVID-19 manufacturing.
September 13, 2023
 · 
3 min read
 · 
Kate Goodwin
Pictured: Money growth/iStock, RomoloTavani
Rome Secures J&J, BMS Investment to Boost Series B Total to $149M
A $72 million Series B extension includes new investors Johnson & Johnson and Bristol Myers Squibb to take Rome Therapeutics’ lead asset through to Phase I studies in autoimmune disease.
September 12, 2023
 · 
2 min read
 · 
Kate Goodwin
Load More